UNSPSC 51382403: Bromfenac sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula 2C15H11BrNO3.2Na.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ECV571Y37, chemically known as benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, sesquihydrate but more generally known as bromfenac sodium, which bears US NIH Compound Identifier 60725. European Medicines Agency schedules Bromfenac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00874MIG.

UNSPSC 51382403 Bromfenac sodium is a Commodity code that covers pharmaceutical products used in state and local procurement, though recent activity shows minimal alignment with the code's nominal scope. The single recent opportunity posted under this code—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and drug deactivation systems rather than bromfenac, a nonsteroidal anti-inflammatory ophthalmic agent. The mismatch suggests either a tagging error in the source or a significant drift between the code's intended use and current procurement practice. Issuing bodies pursuing similar health-supply contracts span county health departments and community health initiatives, though the sample is too narrow to characterize the broader issuing-body mix across the code.

Geographic activity is limited to Florida based on available recent opportunities. Seminole County's IFB, posted June 30, 2026, with a response deadline of July 26, 2023, requested 1,900 units of naloxone and 800 safe drug deactivation systems for annual delivery in four quarterly shipments to the Seminole County Community Health Building in Sanford, Florida. The procurement required vendors to submit bids electronically, include all shipping and delivery costs, hold drug-free workplace certification and E-Verify compliance, and maintain workers' compensation and commercial general liability insurance. The contract offered a two-year initial term with a one-year renewal option and was subject to a three-month probationary period. The code shows little recent relevant activity overall and should be watched rather than pursued unless sourcing specifically targets bromfenac or closely related ophthalmic pharmaceuticals in state or local procurement channels.